pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Spravato
drug
save

esketamine hydrochloride

Marketedupdated 6mo ago
by Johnson & Johnson Innovative Medicine
Approved
annual revenue · 2024–2024peak $1.0B
2024: $1.0B2024$1.0B
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval68 co-mentions · 17 sources
  • drugesketamine35 co-mentions · 18 sources
  • drugSRX-2535 co-mentions · 18 sources
  • companyChiral Biotech Pharma Pty Ltd1 co-mentions · 1 sources
  • tagMajor Depression1 co-mentions · 1 sources

indications

investigational
Major Depression

all catalysts(1)

phase 1 initiation · 1
Apr 30, 2026
phase 1 initiation
7mo ago
Chiral Biotech Pharma Pty Ltd — esketamine hydrochloride (Phase I Trial Initiation)
esketamine hydrochloride
→

Trials studying esketamine hydrochloride

  • phase4Positioning of Esketamine Treatment in the Real-world Management of Depressionrecruitingn=162

Patent cliff

source: FDA Orange Book
first barrier falls
Mar 20, 2027
120 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (7)

  • Feb 18, 2040method-of-use (U-3813)US 11883526
  • Sep 10, 2035method-of-use (U-3036)US 10869844
  • Sep 10, 2035method-of-use (U-3257)US 11173134
  • Sep 10, 2035method-of-use (U-3035)US 11311500
  • Mar 14, 2034method-of-use (U-3446)US 11446260
  • Mar 5, 2033method-of-use (U-4112)US 8785500
  • Mar 20, 2027method-of-use (U-4112)US 9592207120d

FDA exclusivities (1)

  • Jan 17, 2028I-959Indication (3y)1.2y

News(10)

  • HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s Day
    Ibogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration.
    biospace · 6d ago
  • ARPA-H bets $4.9 million on ibogaine for PTSD treatment in veterans
    The U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post-traumatic stress disorder (PTSD).
    fiercebiotech · 7d ago
  • Delix raises $100M to advance at-home psychedelic without hallucinogenic effects
    The series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.
    biospace · 9d ago
  • Delix raises $100M to advance at-home psychedelic without hallucinatory effects
    The series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.
    biospace · 9d ago
  • J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression
    Delix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression.
    fiercebiotech · 10d ago
  • Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’
    The CEO of Compass Pathways said the company, whose psychedelic therapy is set for regulatory review this year, is prepared to “go slow before we go fast.”
    stat · 1mo ago
  • How J&J paved the way for Compass’ coming psychedelic drug launch
    In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Sprav…
    biopharma_dive · 1mo ago
  • Deep dive: Psychedelics back on FDA’s doorstep
    BioSpace takes stock of the psychedelic therapeutics space, which is once again on the cusp of its first FDA approval.
    biospace · 2mo ago
  • Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near market
    Safety and access were top of mind at Monday’s public hearing exploring the regulation of psychedelic therapies. "The medicine opens the door,” NeuroAlchemy co-founder Michaela Vogt said during the…
    biospace · 2mo ago
  • Psychedelic therapies ride wave of public favor into FDA hearing
    Heading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds—to match r…
    biospace · 2mo ago
view all news mentions →
brand
Spravato
generic
esketamine hydrochloride
indication
Major Depressive Disorder
phase
marketed
approved
2019-03-05
Data sources
openFDA · ClinicalTrials.gov
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?